US 12,070,448 B2
Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
Eun Ju Choi, Gyeonggi-do (KR); Hye Won Shin, Gyeonggi-do (KR); and Yu Jin Shin, Gyeonggi-do (KR)
Assigned to SK BIOPHARMACEUTICALS CO., LTD., Gyeonggi-do (KR)
Appl. No. 17/277,856
Filed by SK BIOPHARMACEUTICALS CO., LTD., Gyeonggi-do (KR)
PCT Filed Sep. 20, 2019, PCT No. PCT/KR2019/012184
§ 371(c)(1), (2) Date Mar. 19, 2021,
PCT Pub. No. WO2020/060252, PCT Pub. Date Mar. 26, 2020.
Claims priority of provisional application 62/734,406, filed on Sep. 21, 2018.
Prior Publication US 2021/0346348 A1, Nov. 11, 2021
Int. Cl. A61K 31/41 (2006.01); A61P 25/08 (2006.01)
CPC A61K 31/41 (2013.01) [A61P 25/08 (2018.01)] 8 Claims
 
1. A method for alleviating or treating status epilepticus, comprising:
administering to a subject in need thereof a therapeutically effective amount of a compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof:

OG Complex Work Unit Chemistry
wherein,
R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, C1-C8 alkyl, halo-C1-C8 alkyl, C1-C8 thioalkoxy and C1-C8 alkoxy; and
one of A1 and A2 is CH, and the other is N.